bromocriptine + methimazole

This is a combination of two small molecule pharmaceuticals, bromocriptine and methimazole. Bromocriptine is a dopamine D2 receptor agonist primarily used to treat hyperprolactinemia, Parkinson's disease, and acromegaly by inhibiting prolactin secretion and stimulating dopaminergic receptors[2]. Methimazole is an antithyroid thionamide agent that inhibits thyroid peroxidase, reducing the synthesis of thyroid hormones and treating hyperthyroidism[1][5]. There are no known fixed-dose combination products containing both drugs; their co-administration may be considered in rare clinical scenarios such as complex pituitary-thyroid axis disorders. The pharmacological rationale for combining these agents would be to address conditions involving both abnormal prolactin secretion and thyroid hormone excess or resistance[7].